include use of artificial ultraviolet A (UVA) or ultraviolet B (UVB) light either alone or in
combination with medications.
Increasing prevalence of psoriasis coupled with early diagnosis to propel growth of psoriasis
treatment market
The growth of psoriasis treatment market is projected to gain traction in North America owing
to large patient pool in this region. Also, better medical facilities, commercialization of new
diagnostic technology, medical policies, and favorable reimbursement policies are factors fueling
growth of psoriasis treatment market. According to the International Federation of Psoriasis
Associations (IFPA), around 3% of the world’s population has some form of psoriasis. According
to a study published in Cleveland Clinic in September 2013, there are around 150,000 new
cases of psoriasis reported each year in the U.S. According to a study published in Medical
Journal of Malaysia, in 2015 prevalence of psoriasis varies between 2.0% to 3.0% worldwide.
Incidence rate is highest among Caucasians and lowest among Japanese and Africans. The study
states that prevalence rate of psoriasis in Japan is 0.05% to 0.1%, as compared to China 0.5%
and Taiwan 0.2%, and in India, the prevalence of psoriasis was reported in the range of 0.4%
to 2.8%. High prevalence and increasing incidence propels growth of the psoriasis treatment
market.
Browse Complete Report For More Information @ http://bit.ly/324IpfB
Key players involved in psoriasis treatment market
There are many global players operating in the global psoriasis treatment market. This includes
Glenmark Pharmaceuticals Limited, Sun Pharmaceuticals Industries Ltd., Cipla Ltd., Johnson &
Johnson, Rowan Bioceuticals Private Limited, Stiefel Laboratories Inc. (GlaxoSmithKline plc),
Win Medicare Pvt. Ltd., and Novartis AG. Novartis AG acquired Ziarco Pharma Ltd— a U.K.-
based dermatology therapeutics firm—in December 2016 to acquire a pipeline of oral and
topical products for treatment of psoriasis. Acquisition of the potentially first-in-class therapy
would bolster dermatology portfolio and pipeline of Novartis. Ziarco completed Phase II trial, a
proof-of-concept study with ZPL-389.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.